Ignite Creation Date:
2024-05-06 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03601013
Status:
COMPLETED
Last Update Posted:
2019-05-07
First Post:
2018-03-27
Brief Title:
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
Sponsor:
Cardiovascular Academy Society Turkey
Organization:
Cardiovascular Academy Society Turkey
Study Overview
Official Title:
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coronary Artery Disease CAD is leading cause of death worldwide Most of them underwent coronary angiography and they have to use dual anti-platelet therapy As mentioned novel guidelines for CAD the estimated number of patients requiring dual anti-platelet therapy has increased over time and DAPT time is controversial Acting on the behalf of 2017 ESC focused update on dual anti-platelet therapy in coronary artery disease developed in collaboration with EACTS guideline this study is amid to determine PRECISE-DAPT score which predicts out of hospital bleeding risk in patients receiving dual anti-platelet treatment and to detect the prevalence of patients with high bleeding risk and to determine DAPT score which predicts benefitrisk ratio of continuing or discontinuing dual ant-iplatelet therapy after 12 months and to detect the prevalence of patients with high ischemic or hemorrhagic complication risk in centers included in this study
Detailed Description:
Design
The study is a national multicenter non-interventional observational prospective registry
Population
Patients older than 18 years old of age have acute coronary syndrome or percutaneous coronary intervention electively and with available admission hemoglobin white blood cell and creatine clearance data will be enrolled for Precise-DAPTand Patients older than 18 years old of age and completed 12 months of dual anti-platelet therapy without having hemorrhage and ischemic coronary event and with available data of age history of smoking presence of diabetes mellitus history of percutaneous coronary intervention paclitaxel eluting stent stent diameter history of myocardial infarction saphenous vein graft intervention ejection fraction or presence of heart failure Patients that do not approve informed consent will be excluded
Aim
This study is amid to investigate the demographic and clinical profile of patients with CAD and on dual anti-platelet therapy mean precise -DAPT and DAPT scores of Turkey
The study is a national multicenter non-interventional observational prospective registry
Population
Patients older than 18 years old of age have acute coronary syndrome or percutaneous coronary intervention electively and with available admission hemoglobin white blood cell and creatine clearance data will be enrolled for Precise-DAPTand Patients older than 18 years old of age and completed 12 months of dual anti-platelet therapy without having hemorrhage and ischemic coronary event and with available data of age history of smoking presence of diabetes mellitus history of percutaneous coronary intervention paclitaxel eluting stent stent diameter history of myocardial infarction saphenous vein graft intervention ejection fraction or presence of heart failure Patients that do not approve informed consent will be excluded
Aim
This study is amid to investigate the demographic and clinical profile of patients with CAD and on dual anti-platelet therapy mean precise -DAPT and DAPT scores of Turkey
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None